Gyros Protein Technologies introduces Gyrolab Generic Anti-AAV Kit to support gene therapy development Post author: Post published:June 17, 2024 Post category:uncategorized Ready-to-use kit enables detection of binding antibodies against AAV vectors without the need for serotype-specific assays. You Might Also Like Transforming drug discovery with AI June 21, 2024 Food in sight? The liver is ready! April 25, 2024 Moffitt study identifies predictive biomarkers for immunotherapy in merkel cell carcinoma July 26, 2024
Moffitt study identifies predictive biomarkers for immunotherapy in merkel cell carcinoma July 26, 2024